The Dermatologic And Ophthalmic Drugs Advisory Committee (DODAC) receives requests for technical and clinical evaluation of new drugs by the
U.S. Food and Drug Administration (FDA). The committee, consisting of members from academic and clinical dermatology, ophthalmology, biostatistics, the general public, and the pharmaceutical industry, makes non-binding recommendations to both the
CDER
The Center for Drug Evaluation and Research (CDER, pronounced "see'-der") is a division of the U.S. Food and Drug Administration (FDA) that monitors most drugs as defined in the Food, Drug, and Cosmetic Act. Some biological products are also leg ...
and
CBER divisions of the FDA about the advisability of approving new medications to treat
dermatologic and
ophthalmic conditions.
References
External links
* Dermatologic And Ophthalmic Drugs Advisory Committee, official webpage: https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/default.htm
* FDA Advisory Committees Calendar (including DODAC): https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm
Food and Drug Administration
National agencies for drug regulation
Regulators of biotechnology products
Pharmacy organizations in the United States
{{Drug-stub